https://www.msn.com/en-us/money/companies/23andme-knows-what-diseases-are-in-your-dna-now-its-looking-for-the-cures/ar-BBPWkAZ?ocid=spartandhp
Having now genotyped the DNA of millions of customers, 23andMe has a trove of data that could be valuable in correlating gene pools with specific traits and illnesses–an especially useful tool for drug makers. That's why in July, pharma giant GlaxoSmithKline made a $300 million investment in the company in exchange for equity and access to the company's data.
"Part of the reason why we started 23andMe," Wojcicki says, "was that we thought we had the potential to dramatically accelerate the pace of research. Now we're able to show something truly meaningful coming out of that mission."